Reviewed & approved by Dr. Nova Reyes · Last checked 2026-10-25. ← Back to Evidence Library

Dapiglutide: what the evidence says

At a glance

What it is: an experimental injected peptide that activates two receptors, GLP-1 (the target of semaglutide) and GLP-2 (the target of teduglutide, a drug for short bowel syndrome). ^{R1, R2}

What the evidence says: the only peer-reviewed human trial was small and short, and its weight loss vs placebo (a dummy treatment) was not statistically significant. Larger weight-loss numbers come only from the company. Gut benefits have been shown only in mice. ^{R1, R2, R3, R4}

Biggest risks: nausea and lower appetite in the one trial. Long-term safety is unknown, and with the program paused, more data may never come. Gray-market vials add unknown identity, strength and purity. ^R1


Human Human evidence (weight)	Very limited: one small, short phase 2a RCT (randomized controlled trial; 54 people) with no significant effect; larger results only from the company ^{R1, R4}
Human Short bowel syndrome, gut inflammation	Not rated: no human results found; mouse studies only ^{R2, R3}
Animal Animal evidence	Mouse studies of short bowel syndrome; not rated here ^{R2, R3}
Regulatory	Not FDA-approved (no Drugs@FDA record) · Program paused by Zealand (Nov 2025) ^{R4, R5} · EU, Japan, China: UNVERIFIED not checked against EMA, PMDA or NMPA · WADA: not named; S0 (unapproved substances) likely applies ^R6
Established human dose	None. There is no label. Trial study arms are listed only in Study details

Evidence verdict: Human (weight): Very limited · Short bowel and gut: not rated (animal only) · Animal: mouse studies, not rated here Card verdict: Very limited (one small phase 1 trial showed no significant weight loss; program paused Nov 2025)

This page reports what studies used. It is not dosing advice.

Legend: HUMAN data · ANIMAL / LAB data · UNKNOWN · UNVERIFIED: not yet confirmed against a primary source

What is it?

Dapiglutide is a lab-made peptide that switches on both the GLP-1 receptor and the GLP-2 receptor. ^R1 GLP-1 action lowers appetite. GLP-2 helps the gut lining grow and may strengthen the gut barrier, which is why it was studied for short bowel syndrome and gut inflammation. ^{R1, R2, R3}

Does it help weight loss?

Human Phase 2a (investigator-run, Denmark): in 54 adults with obesity, the higher study arm lost 2.1% more weight than placebo in a short trial. This was not statistically significant. ^R1 The trial was funded by an unrestricted grant from Zealand. ^R1
Human Company phase 1b: Zealand reported larger weight losses in its own early trials using higher amounts, but those company-reported figures have not been published in a peer-reviewed journal and are kept in Study details below. ^R4 [UNVERIFIED: company figures; no peer-reviewed paper found on PubMed.]
Unknown Whether larger amounts would work and be tolerated over longer periods.

Does it help short bowel syndrome or the gut?

Animal In mice with surgically shortened bowels, dapiglutide increased gut growth, slowed transit, reduced fluid loss in stool and helped weight recovery. ^R2 It also tightened parts of the gut barrier in the small intestine. ^R3
Unknown No human results for short bowel syndrome were found.

Is it safe?

What the trial reported:

Caution Common side effects: reduced appetite and nausea. No one stopped because of side effects caused by the drug, and dropouts were low (0% to 11%). ^R1
Caution GLP-1 class risks: Dapiglutide acts on the GLP-1 receptor, so the risks known for that drug class (pancreatitis, gallbladder disease, rodent thyroid tumors, low blood sugar with insulin or sulfonylureas, older blood-sugar-lowering pills) are reasonable to expect; see the semaglutide page. Unknown The abstracts we reviewed do not report rates of these events.
Caution GLP-2 action: GLP-2 drugs make the gut lining grow. Unknown Whether this carries long-term risks with dapiglutide has not been studied in people.
Unknown Long-term safety and rare harms are unknown.

Compounded and gray-market Dapiglutide: extra risks

Caution Unregulated "research" vials from a paused program. Because clinical development was paused in November 2025 and no approved product exists, any vial sold online has no regulatory quality control, and its identity, strength and sterility are unknown. ^{R4, R5}
Caution Don't stack with other GLP-1 drugs. Taking Dapiglutide with semaglutide, tirzepatide, retatrutide or similar drugs means two drugs acting on the same receptor, which no trial on this page tested. Unknown
Caution Measuring mistakes. FDA has reported people hospitalized after drawing up too much from multi-injection GLP-1 vials. The same syringe-marking problem applies here. See the section on measuring mistakes on our semaglutide page.

What we don't know

Unknown What is actually in a given gray-market vial
Unknown Whether dapiglutide causes meaningful weight loss in a well-powered trial
Unknown Whether it helps short bowel syndrome or gut inflammation in people
Unknown Whether development will restart ^{R4, R5}

Is it legal?

Not FDA-approved; no Drugs@FDA record was found (openFDA search, Oct 24, 2026). Zealand lists the program as paused. ^R4 EU, Japan, China: UNVERIFIED not checked against EMA, PMDA or NMPA. WADA: not named on the 2026 Prohibited List; S0 bans at all times any unapproved substance in development that no other section covers, which describes Dapiglutide ^R6. WADA has not ruled on Dapiglutide by name. As of Oct 24, 2026.

What's in the vial?

Real dapiglutide is not available outside past clinical trials. We have not found published lab tests of gray-market Dapiglutide. Under the Open Peptide Standard, a GLP-1 vial overfilled by more than 20% is a critical fail (draft threshold). See results at /tests/. A passing test covers one batch, tested on one date. It does not mean the compound itself is safe.

What do users report?

Self-report, not evidence.

Unknown TBD. We'll only list this once we can cite a public source.

Study details

These are doses researchers used, not recommendations.

R1 Human: Weight

Study	People	Route	Dose used	Follow-up	Reported	Side effects / dropouts	Citation
Phase 2a, investigator-initiated (Nielsen 2026), Denmark, NCT05788601	54	Subcutaneous	4 or 6 mg once weekly vs placebo, no lifestyle program	12 wk	6 mg: −2.1% vs placebo (95% CI −4.3 to 0.2; p=0.076)	Reduced appetite, nausea; dropouts 0% (placebo), 11% (4 mg), 6% (6 mg); none for drug AEs	PMID 41768273
Zealand phase 1b (company)	Not verified	Subcutaneous	Higher amounts than above	Not verified	Part 1 up to −8.3% placebo-corrected; part 2 −11.6% vs −0.2%	Not verified	R4 UNVERIFIED

R2, R3 Animal

R2 Reiner 2022, mouse short bowel model: intestinal growth, slower transit, less stool water, weight recovery. PMID 34705281
R3 Reiner 2022, mouse: jejunal barrier effects. PMID 35580981

R4, R5 Company and news (as of Oct 24, 2026)

R4 Zealand Pharma, Dapiglutide (program paused). UNVERIFIED Company source.
R5 Fierce Biotech, Zealand hits pause on dual GLP-1/GLP-2 asset. Secondary source.
FDA: no Drugs@FDA record (openFDA query, Oct 24, 2026). EMA, PMDA, NMPA: UNVERIFIED not checked.

Full reference list (all PMIDs verified on PubMed, Oct 24, 2026)

Nielsen CK, et al. EClinicalMedicine. 2026;93:103801. doi:10.1016/j.eclinm.2026.103801. PMID 41768273
Reiner J, et al. JPEN J Parenter Enteral Nutr. 2022;46(5):1107-1118. doi:10.1002/jpen.2286. PMID 34705281
Reiner J, et al. Ann N Y Acad Sci. 2022;1514(1):132-141. doi:10.1111/nyas.14791. PMID 35580981
Zealand Pharma. Dapiglutide (program paused), pipeline page. https://www.zealandpharma.com/pipeline/dapiglutide-program-paused/
Fierce Biotech. Zealand pumps brakes on development of dual GLP-1/GLP-2 agonist. November 2025. https://www.fiercebiotech.com/biotech/zealand-hits-pause-dual-glp-1glp-2-asset-cmo-cites-increasingly-crowded-metabolic
WADA. World Anti-Doping Code International Standard: Prohibited List 2026 (in force Jan 1, 2026). https://www.wada-ama.org/sites/default/files/2025-09/2026list_en_final_clean_september_2025.pdf (text read Oct 24, 2026)

Disclaimer

This page is for education and harm reduction. It is not medical advice and not a recommendation to use Dapiglutide. Please talk to a clinician you trust before making medical decisions, seek care right away for severe stomach pain or repeated vomiting, and report problems to FDA MedWatch (https://www.fda.gov/safety/medwatch).

Approved for Adam Greene by Dr. Nova Reyes, 2026-10-25.